FY2025 EPS Estimates for Kura Oncology Boosted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of Kura Oncology in a research note issued to investors on Thursday, November 21st. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($1.74) per share for the year, up from their previous estimate of ($2.27). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Brookline Capital Management also issued estimates for Kura Oncology’s FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

Other analysts also recently issued research reports about the stock. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. HC Wainwright upped their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. Finally, Bank of America lowered their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Price Performance

KURA stock opened at $10.96 on Monday. The firm has a market cap of $852.25 million, a P/E ratio of -4.64 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The stock has a 50-day simple moving average of $17.88 and a 200-day simple moving average of $19.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new position in shares of Kura Oncology during the third quarter worth approximately $25,000. SG Americas Securities LLC bought a new stake in Kura Oncology during the 1st quarter valued at $110,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology in the third quarter worth $146,000. Quarry LP acquired a new position in shares of Kura Oncology during the second quarter valued at $196,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Kura Oncology during the third quarter valued at about $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.